{"id":49698,"date":"2024-06-24T18:34:07","date_gmt":"2024-06-24T10:34:07","guid":{"rendered":"https:\/\/biopioneer.com.tw\/?p=49698"},"modified":"2024-07-18T18:00:10","modified_gmt":"2024-07-18T10:00:10","slug":"arca-egfp-mrna-apexbio%e8%b2%a8%e8%99%9f-r1001","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=49698","title":{"rendered":"ARCA EGFP mRNA | APExBIO\u8ca8\u865f R1001"},"content":{"rendered":"<p><span style=\"color: #33cccc;\"><a style=\"color: #33cccc;\" href=\"https:\/\/biopioneer.com.tw\/?p=49698&amp;preview=true\"><span style=\"font-size: 12pt;\"><strong>ARCA EGFP mRNA APExBIO\u8ca8\u865f R1001<\/strong><\/span><\/a><\/span><\/p>\n<p><span style=\"color: #800000;\"><strong><span style=\"font-size: 12pt;\">ARCA EGFP mRNA\u7522\u54c1\u4ecb\u7d39<\/span><\/strong><\/span><\/p>\n<p>EGFP (enhanced green fluorescent protein, EGFP)\uff08\u589e\u5f37\u578b\u7da0\u8272\u87a2\u5149\u86cb\u767d\uff09mRNA \u8f49\u67d3\u7d30\u80de\u5f8c\u53ef\u8868\u9054\u589e\u5f37\u578b\u7da0\u8272\u87a2\u5149(enhanced green fluorescence )\uff0c\u662f\u4e00\u7a2e\u76f4\u63a5\u6aa2\u6e2c\u5831\u544a\u57fa\u56e0mRNA\uff0c\u53ef\u4f5c\u70ba\u5c0d\u7167\uff0c\u900f\u904e\u5404\u7a2e\u57fa\u65bc\u87a2\u5149\u7684\u6aa2\u6e2c\u4f86\u7814\u7a76\u54fa\u4e73\u52d5\u7269\u7d30\u80de\u4e2d\u7684\u8f49\u67d3\u548c\u8868\u9054\u3002\u60a8\u53ef\u4ee5\u5728 509 nm \u8655\u89c0\u5bdf\u87a2\u5149\u3002\u6211\u5011\u7684\u7522\u54c1\u5df2\u7d93\u900f\u904e\u9ad8\u6548\u7684\u5171\u8f49\u9304\u52a0\u5e3d\u65b9\u6cd5\u7528ARCA\u9032\u884c\u4fee\u98fe\uff0c\u9019\u610f\u5473\u8457\u5927\u591a\u6578mRNA\u5177\u6709Cap 0\u7d50\u69cb\u3002\u5b83\u662f\u6bd4\u7121\u5e3dmRNA\u66f4\u6210\u719f\u7684mRNA\uff0c\u4e26\u4fdd\u6301\u66f4\u7a69\u5b9a\u7684\u72c0\u614b\uff0c\u5f9e\u800c\u5728\u8f49\u67d3\u7684\u54fa\u4e73\u52d5\u7269\u7d30\u80de\u4e2d\u5177\u6709\u66f4\u9ad8\u7684\u8868\u9054\u6548\u7387\u3002 ARCA \u80fd\u5920\u50c5\u4ee5\u6b63\u78ba\u7684\u65b9\u5411\u63d2\u5165\uff0c\u5f9e\u800c\u5f62\u6210 mRNA\uff0c\u5176\u7ffb\u8b6f\u6548\u7387\u662f mCAP \u8d77\u59cb\u7684 mRNA \u7684\u5169\u500d\u3002ARCA EGFP mRNA \u7684\u5347\u7d1a\u7248\u672c\u73fe\u5df2\u63a8\u51fa\uff0c\u8acb\u67e5\u770b R1007 ARCA EGFP mRNA (5-moUTP) \u4ee5\u4e86\u89e3\u66f4\u591a\u8a73\u7d30\u8cc7\u8a0a\u3002<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2023\/11\/2-EZ-Cap%E2%84%A2-Cy5-EGFP-mRNA-5-moUTP-APExBIO%E8%B2%A8%E8%99%9F-R1011.png\" \/><\/p>\n<p><a href=\" http:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2024\/06\/1-ARCA-EGFP-mRNA-APExBIO\u8ca8\u865f-R1001.pdf\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone\" src=\"http:\/\/biopioneer.com.tw\/wp-content\/uploads\/2023\/02\/COA%E6%96%87%E4%BB%B6_%E5%B7%A5%E4%BD%9C%E5%8D%80%E5%9F%9F-1.jpg\" alt=\"COA\u6587\u4ef6_\u5de5\u4f5c\u5340\u57df 1\" width=\"146\" height=\"60\" \/><\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" class=\"\" src=\"https:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2024\/06\/2-ARCA-EGFP-mRNA-APExBIO%E8%B2%A8%E8%99%9F-R1001.jpg\" width=\"500\" height=\"375\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2024\/06\/2-ARCA-EGFP-mRNA-APExBIO%E8%B2%A8%E8%99%9F-R1001-1.png\" \/><\/p>\n<table border=\"0\" width=\"100%\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"30%\"><strong>Cell line<\/strong><\/td>\n<td width=\"70%\">HEK293T<\/td>\n<\/tr>\n<tr>\n<td><strong>Tissue culture plate<\/strong><\/td>\n<td>48-well tissue culture plate<\/td>\n<\/tr>\n<tr>\n<td><strong>The plating cell volume<\/strong><\/td>\n<td>50,000<\/td>\n<\/tr>\n<tr>\n<td><strong>Cell density before transfection<\/strong><\/td>\n<td>cell fusion degree 50%-60%<\/td>\n<\/tr>\n<tr>\n<td><strong>Transfection conditions<\/strong><\/td>\n<td>After culturing for 17 hours, transfection (1\u03bcg mRNA+2\u03bcL lipofectamine 2000) in serum- and antibiotic-free medium, 4 hours later, change to complete medium to return to normal growth environment and perform fluorescence photography after 24 hours.<\/td>\n<\/tr>\n<tr>\n<td><strong>RNA amount and transfection reagent<\/strong><\/td>\n<td>1\u03bcg mRNA and 2\u03bcL lipofectamine 2000 are prepared according to the instructions<\/td>\n<\/tr>\n<tr>\n<td><strong>Transfection efficiency<\/strong><\/td>\n<td>above 90% transfection efficiency<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div id=\"cite\" class=\"tbar\">\n<h2><span style=\"color: #800000;\"><strong><span style=\"font-size: 12pt;\">Product Citation<\/span><\/strong><\/span><\/h2>\n<\/div>\n<div class=\"detail-table \">\n<div class=\"detail-box-cont\">\n<ul id=\"artul\">\n<li><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38227975\" target=\"_blank\" rel=\"noopener\">1. Peiying Li, et al. &#8220;Targeted mRNA Nanoparticles Ameliorate Blood\u2013Brain Barrier Disruption Postischemic Stroke by Modulating Microglia Polarization.&#8221; ACS Nano. 2024 Jan 30;18(4):3260-3275. PMID: 38227975<\/a><\/li>\n<li><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37481734\" target=\"_blank\" rel=\"noopener\">2. Yan Liang, Jingge Zhang, et al. &#8220;Biomimetic Mineralized CRISPR\/Cas RNA Nanoparticles for Efficient Tumor-Specific Multiplex Gene Editing.&#8221; ACS Nano. 2023 Aug 8;17(15):15025-15043. PMID: 37481734<\/a><\/li>\n<li><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37349886\" target=\"_blank\" rel=\"noopener\">3. Hao Chen, Lina Guo, et al. &#8220;A General and Efficient Strategy for Gene Delivery Based on Tea Polyphenols Intercalation and Self\u2010Polymerization.&#8221; Adv Sci (Weinh). 2023 Aug;10(24):e2302620. PMID: 37349886<\/a><\/li>\n<li><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36584740\" target=\"_blank\" rel=\"noopener\">4. Qiming Yin,\u00a0Xiang Song, et al. &#8220;Incorporation of glycyrrhizic acid and polyene phosphatidylcholine in lipid nanoparticles ameliorates acute liver injury via delivering p65 siRNA.&#8221; Nanomedicine. 2022 Dec 27;48:102649. PMID: 36584740<\/a><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p><span style=\"color: #800000;\"><strong><span style=\"font-size: 12pt;\"><a style=\"color: #800000;\" href=\"http:\/\/www.apexbt.com\/\">APExBIO\u53f0\u7063\u4ee3\u7406\u5546<\/a><\/span><\/strong><\/span><\/p>\n<p><span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/www.apexbt.com\">https:\/\/www.apexbt.com<\/a><\/span><\/p>\n<p>APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n<table width=\"1051\">\n<tbody>\n<tr>\n<td width=\"61\">R1001-.1<\/td>\n<td width=\"244\">ARCA EGFP mRNA<\/td>\n<td width=\"746\">Direct-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1001-5<\/td>\n<td>ARCA EGFP mRNA<\/td>\n<td>Direct-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1001-1<\/td>\n<td>ARCA EGFP mRNA<\/td>\n<td>Direct-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1005-.1<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1005-5<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1005-1<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1006-.1<\/td>\n<td>SpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n<tr>\n<td>R1006-5<\/td>\n<td>SpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n<tr>\n<td>R1006-1<\/td>\n<td>SpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n<tr>\n<td>R1007-.1<\/td>\n<td>ARCA EGFP mRNA (5-moUTP)<\/td>\n<td>New modification with better performance &#8212; direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1007-5<\/td>\n<td>ARCA EGFP mRNA (5-moUTP)<\/td>\n<td>New modification with better performance &#8212; direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1007-1<\/td>\n<td>ARCA EGFP mRNA (5-moUTP)<\/td>\n<td>New modification with better performance &#8212; direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1008-.1<\/td>\n<td>ARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1008-5<\/td>\n<td>ARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1008-1<\/td>\n<td>ARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1009-.1<\/td>\n<td>ARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1009-5<\/td>\n<td>ARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1009-1<\/td>\n<td>ARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1010-.1<\/td>\n<td>EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1010-5<\/td>\n<td>EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1010-1<\/td>\n<td>EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1011-.1<\/td>\n<td>EZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1011-5<\/td>\n<td>EZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1011-1<\/td>\n<td>EZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1012-.1<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1012-5<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1012-1<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1013-.1<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1013-5<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1013-1<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1015-.1<\/td>\n<td>EZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n<tr>\n<td>R1015-5<\/td>\n<td>EZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n<tr>\n<td>R1015-1<\/td>\n<td>EZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n<tr>\n<td>R1016-.1<\/td>\n<td>EZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1016-5<\/td>\n<td>EZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1016-1<\/td>\n<td>EZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1017-.1<\/td>\n<td>EZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\n<td>mCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1017-5<\/td>\n<td>EZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\n<td>mCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1017-1<\/td>\n<td>EZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\n<td>mCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1018-.1<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1018-5<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1018-1<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1020-.1<\/td>\n<td>EZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\n<td>Human erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1020-5<\/td>\n<td>EZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\n<td>Human erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1020-1<\/td>\n<td>EZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\n<td>Human erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1021-.1<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1021-5<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1021-1<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1022-.1<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1022-5<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1022-1<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1023-.1<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA<\/td>\n<td>Human p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1023-5<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA<\/td>\n<td>Human p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1023-1<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA<\/td>\n<td>Human p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1024-.1<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\n<td>Human p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1024-5<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\n<td>Human p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1024-1<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\n<td>Human p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1025-.1<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1025-5<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1025-1<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1026-.1<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1026-5<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1026-1<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ARCA EGFP mRNA APExBIO\u8ca8\u865f R1001 ARCA EGFP mRNA\u7522\u54c1\u4ecb\u7d39 EGFP  [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":47343,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5368],"tags":[6635],"_links":{"self":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/49698"}],"collection":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49698"}],"version-history":[{"count":3,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/49698\/revisions"}],"predecessor-version":[{"id":49702,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/49698\/revisions\/49702"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/47343"}],"wp:attachment":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}